X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CF102 (namodenoson) is a orally bioavailable small molecule drug that binds to A3AR. It is being evaluated for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Under the agreement, Can-fite will focus on their development of CF102 (namodenoson), which is a selective agonist at the A3 adenosine receptor, for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ewopharma AG
Deal Size: $42.7 million Upfront Cash: $2.2 million
Deal Type: Licensing Agreement January 30, 2024
Details:
CF101 (piclidenoson), a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. It is under phase 3 clinical development for the treatment of children suffering from psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The company intends to use the net proceeds for funding research and development and clinical trials for its pipeline, including CF101 (piclidenoson), an agonist to the A3 adenosine receptor, currently in a Phase III clinical study for the treatment of psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2023
Details:
Namodenoson is a small orally bioavailable drug that binds to the A3 adenosine receptor (A3AR). It was evaluated in Phase II trials for 2nd line treatment for hepatocellular carcinoma, & as a treatment for non-alcoholic fatty liver disease & non-alcoholic steatohepatitis.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
The agreement aims for the development of CF101 (piclidenoson), a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug, for the treatment of Lowe Syndrome, a high medical need with no drug available.
Lead Product(s): Piclidenoson
Therapeutic Area: Genetic Disease Product Name: CF101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fondazione Telethon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes like psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
